Forkhead Bio is harnessing the intrinsic capabilities of cell conversion and regeneration in order to develop transformative therapies that improve patient’s lives.
Initially, we aim to exploit this discovery by developing an oral agent — a Foxin™ pill — to treat insulin-dependent diabetes by restoring normal insulin production, and normalizing glucose metabolism.
We know that time is our most precious resource. There is no break, no “time out” for the patients and loved ones we aim to serve. We are driven with unrelenting persistence to bring meaningful relief to patients as fast as we can.
We are genuinely excited by the potential of our technology, and aim to convey that excitement without exaggeration or hype. That means speaking truth to all stakeholders, to our future customers, to our investors and partners, and also to ourselves and each other, confident that our most compelling story and most faithful guide to our future lies in the evidence we assemble and results we achieve.
We are collectively dedicated to the mission of our company to improve the lives of patients by delivering transformative therapies. Our motivation is personal, purposeful and shared. With excellence as our goal, our success is measured by our care and support of one another, knowing that our highest aspirations cannot be achieved by any one of us alone.
We seek first to understand the human burden of the diseases we want to treat, and to use that understanding to guide and shape both our long term vision and our daily tasks. As family, friend or care-provider, we are awed by the courage and resilience of those who shoulder this burden. With gratitude and respect, we humbly appeal for their help, wisdom and support.
Leadership Team Our team
- Charles Queenan ME, MBA Co-Founder · Director · CEO
- Dr. Domenico Accili MD Co-Founder · Director · Chair SAB
- Dr. Hua Lin Ph.D. Co-Founder · CSO
- Dr. Sandro Belvedere Ph.D. Vice President of Chemistry